Inhibitory effect of calcium channel blockers on human mesangial cell growth: Evidence for actions independent of L-type Ca2+ channels

Kidney International

Volumn 49, Issue 3, 1996, Pages 868-879

  Orth, Stephan R ^a   Nobiling, Rainer ^a   Bönisch, Sabine ^a   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DEVAPAMIL; DILTIAZEM; EMOPAMIL; NIFEDIPINE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS; ENANTIOMER; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESANGIUM CELL; PRIORITY JOURNAL; STEREOSPECIFICITY;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ADULT; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL COUNT; CELL DIVISION; CELLS, CULTURED; DNA; EXTRACELLULAR MATRIX PROTEINS; GLOMERULAR MESANGIUM; HUMANS; POTASSIUM;

EID: 0029930411     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.120     Document Type: Article

References (70)

1. BRUNNER FP, BLOCK HA, HERMLE M, THIEL G, MIHATSCH MJ: Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 6:420-427, 1991
2. JACKSON B, JOHNSTON CI: The contribution of systemic hypertension to progression of chronic renal failure in the remnant kidney: Effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 6:495-501, 1988
3. WENZEL UO, TROSCHAU G, SCHOEPPE W, HELMCHEN U, SCHWIETZER G: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 20:233-241, 1992
4. HARRIS DCH, HAMMOND WS, BURKE TJ, SCHRIER RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41-46, 1987
5. AGUAS AP, NICKERSON PA: Effect of verapamil on blood pressure and lesions in heart and kidney of rats made hypertensive by deoxycorticosterone (DOC). Am J Pathol 110:48-54, 1983
6. DWORKIN LD, BENSTEIN JA, PARKER M, TOLBERT E, FEINER HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808-814, 1993
7. DWORKIN LD, LEVIN RI, BENSTEIN JA, PARKER M, ULLIAN ME, KIM Y, FEINER HD: Effects of nifidepine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259:F598-F604, 1990
8. DWORKIN LD, FEINER HD, PARKER M, TOLBERT E: Effects of nifidipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39:1112-1117, 1991
9. IRZYNIEC T, MALL G, GREBER D, RITZ E: Beneficial effect of nifidipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 5:437-443, 1992
10. JARUSIRIPIPAT C, CHAN L, SHAPIRO JI, SCHRIER RW: Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. J Pharmacol Exp Ther 260:243-247, 1992
11. ELIAHOU HE, COHEN D, HERZOG D, SHECHTER P, SERBAN I, KAPULER S, SCHIBY G, GAVENDO S: The control of hypertension and its effect on renal function in rat remnant kidney. Nephrol Dial Transplant 3:38-44, 1988
12. WHITTY MR, JACKSON B: Diabetic nephropathy in the rat: Differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. Diabetes Res 8:91-96, 1988
13. LOUTZENHISER R, EPSTEIN M: Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249:F619-F629, 1985
14. SHULTZ PJ, RAIJ L: Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 15(Suppl I):I-76-I-80, 1990
15. ROTH M, KEUL R, EMMONS LR, HÖRL WH, BLOCK LH: Manidipine regulates the transcription of cytokine genes. Proc Natl Acad Sci USA 89:4071-4075, 1992
16. ROTH M, KEUL R, PERRUCHOUD AP, BLOCK LH: Manidipine affects rPDGF-BB-induced gene transcription of low-density lipoprotein receptors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in human mesangial cells. Am Heart J 125:598-603, 1993
17. FUJIWARA Y, OCHI S, IZUMI M, YOKOHAMA K, ARAI M, ANDO A, NAKAOKA A, KAMADA T, UEDA N: Mesangial cell growth in genetically hypertensive rats and effect of calcium antagonists upon this growth. Blood Pressure 1(Suppl 3):22-26, 1992
18. GARCÍA-COSMES P, MORTEZO A, LÓPEZ-NOVOA JM, MACÍAS-NÚNEZ JF: Is renal protection with calcium antagonists possible? Drugs 44(Suppl 1):99-102, 1992
19. DUQUE I: Rodriguez Puyol M, Ruiz P, Gonzales-Rubio M, Diéz Marques L, Rodriguez Puyol D: Calcium channel blockers inhibit hydrogen peroxide-induced proliferation of cultured rat mesangial cells. J Pharmacol Exp Ther 267:612-616, 1993
20. NAWRATH H, RASCHACK M: Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle. J Pharmacol Exp Ther 242:1090-1097, 1987
21. HOFMANN HP, RASCHACK M, UNGER L: (S)-EMOPAMIL, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile. Arzneim-Forsch/Drug Res 39:304-308, 1989
22. ORTH SR, WEINREICH T, BÖNISCH S, WEIH M, RITZ E: Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 3:23-33, 1995
23. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450, 1985
24. NOBILING R, BÜHRLE CP: A microscope fluorimeter using multiple-wavelength excitation for ultrasensitive single-cell emission spectrometry. J Microsc 156:149-161, 1989
25. 3 metabolites in cultured rat mesangial cells. Biochem Biophys Res Commun 180:833-840, 1991
26. FABIATO A, FABIATO F: Calculator programms for computing the composition of the solutions containing multiple metals and ligands used for experiments in skinned muscle cells. J Physiol Paris 75:463-505, 1979
27. i signaling but potentiates endothelin's effect on c-fos and c-jun induction in vascular smooth muscle and glomerular mesangial cells. Am Heart J 125:589-597, 1993
28. HESKETH TR, MOORE JP, MORRIS JDH, TAYLOR MV, ROGERS J, SMITH GA, METCALFE JC: A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells. Nature 313: 481-484, 1985
29. MORGAN JI, CURRAN T: Role of ion flux in the control of c-fos expression. Nature 322:552-555, 1986
30. MIX LL, DINERSTEIN RJ, VILLEREAL ML: Mitogens and Melittin stimulate an increase in intracellular free calcium concentration in human fibroblasts. Biochem Biophys Res Commun 119:69-75, 1984
31. RALPH RK: Cyclic AMP. calcium and control of cell growth. FEBS Lett 161:1-8, 1983
32. NISHIO M, TSUKAHARA H, HIRAOKA M, SUDO M, KIGOSHI S, MURAMATSU I: Calcium channel current in cultured rat mesangial cells. Mol Pharmacol 43:96-99, 1993
33. 2+-channel activity. Cell Calcium 14:387-396, 1993
34. YU Y-M, LERMIOGLU F, HASSID A: Modulation of Ca by agents affecting voltage-sensitive Ca channels in mesangial cells. Am J Physiol 257:F1094-F1099, 1989
35. IIJIMA K, MOORE LC, GOLIGORSKY MS: Syncytial organization of cultured rat mesangial cells. Am J Physiol 260:F848-F855, 1991
36. THOMA K, KLIMEK R: Untersuchungen zur Photoinstabilität von Nifedipin. 1. Mitt.: Zersetzungskinetik und Reaktionsmechanismus. Pharm Ind 47:207-215, 1985
37. 2+ entry directly activates contraction in frog heart. Nature 304:635-638, 1983
38. 2+ signaling by distinct endothelin peptides in glomerular mesangial cells. Exp Cell Res 192:148-156, 1991
39. MENÈ P, TETI A, PUGLIESE F, CINOTTI GA: Calcium release-activated calcium influx in cultured human mesangial cells. Kidney Int 46:122-128, 1994
40. FLOEGE J, ENG E, YOUNG BA, JOHNSON RJ: Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int 43(Suppl 39):S47-S57, 1993
41. HARRIS RC, HOOVER RL, JACOBSON HR, BADR KF: Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 82:1028-1039, 1988
42. PERICO N, REMUZZI G: Role of endothelin in glomerular injury. Kidney Int 43 (Suppl 39):S76-S80, 1993
43. FOLLATH F, HA HR, SCHÜTZ E, BÜHLER FR: Pharmacokinetics of conventional and slow-release verapamil. Br J Clin Pharmacol 21: 149S-153S, 1986
44. RASCHACK M, ENGELMANN K: Calcium antagonistic activity and myocardial ischemic protection by both stereoisomers of verapamil, in Advances in Myocardiology (vol 4), edited by CHAZOV E, SAKS V, RONA G, New York, Plenum Publishing Corporation, 1983, pp 505-512
45. 2+ channel interaction. Trends Pharmacol Sci 11:38-44, 1990
46. FINE RL, PATEL J, CHABNER BA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 85:582-586, 1988
47. KO Y, TOTZKE G, GRAACK GH, HEIDGEN FJ, MEYER ZU BRICKWEDDE MK, DUSING R, VETTER H, SACHINIDIS A: Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells. J Hypertens 11:1171-1178, 1993
48. KO YD, SACHINIDIS A, GRAACK GH, APPENHEIMER M, WIECZOREK AJ, DUSING R, VETTER H: Inhibition of angiotensin II and platelet-derived growth factor-induced vascular smooth muscle cell proliferation by calcium entry blockers. Clin Invest 70:113-117, 1992
49. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA 86:2388-2392, 1989
50. CHOUDHURY GG, BISWAS P, GRANDALIANO G, ABBOUD HE: Involvement of PKC-α in PDGF-mediated mitogenic signaling in human mesangial cells. Am J Physiol 265:F634-F642, 1993
51. BARNETT RL, RUFFINI L, RAMSAMMY L, PASMANTIER R, FRIEDLAENDER MM, NORD EP: Angiotensin-mediated phosphatidylcholine hydrolysis and protein kinase C activation in mesangial cells. Am J Physiol 265: C1100-C1108, 1993
52. SIMONSON MS, HERMAN WH: Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G protein-coupled receptors and pp60c-src. J Biol Chem 268:9347-9357, 1993
53. + current in small-cell lung cancer cells. J Pharmacol Exp Ther 257:184-191, 1991
54. PAPPONE PA, ORTIZ-MIRANDA SI: Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am J Physiol 264:C1014-C1019, 1993
55. ALBRIGHTSON CR, NAMBI P, ZABKO-POTAPOVICH B, DYTKO G, GROOM T: Effect of thrombin on proliferation, contraction and prostaglandin production of rat glomerular mesangial cells in culture. J Pharmacol Exp Ther 263:404-412, 1992
56. 2+ channel antatgonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells. Eur J Pharmacol 244:269-275, 1993
57. + exchange, intracellular pH and vascular smooth muscle cell proliferation. Am J Med Sci 307:S9-S16, 1994
58. BELLO-REUSS E, ERNEST S: Expression and function of P-glycoprotein in human mesangial cells. Am J Physiol 267:C1351-C1358, 1994
59. WEINSTEIN DB, HEIDER JG: Antiatherogenic properties of calcium antagonists. Am J Cardiol 59:163B-172B, 1987
60. 2+ channel blockers. Atherosclerosis 88:109-132, 1991
61. KITAMURA M, MITARAI T, MARUYAMA N, NAGASAWA R, YOSHIDA H, SAKAI O: Mesangial cell behavior in a three-dimensional extracellular matrix. Kidney Int 40:653-661, 1991
62. PABST R, STERZEL RB: Cell renewal of glomerular cell types in normal rats. An autoradiographic study. Kidney Int 24:626-631, 1983
63. KIYAMA S, NANISHI F, TOMOOKA S, OKUDA S, ONOYAMA K, FUJISHIMA M: Inhibitory effects of antihypertensive drugs on mesangial cell proliferation after anti-thymocyte serum (ATS)-induced mesangiolysis in spontaneously hypertensive rats. Life Sci 54:1891-1900, 1994
64. SHIRAKURA S, SANO J, KARASAWA A, KUBO K: Protective effect of benidipine against the development of glomerular sclerosis in experimental nephrotic syndrome. Jpn J Phamacol 59:461-467, 1992
65. REAMS GP, VILLARREAL D, WU Z, WANG X, LUGER AM, BAUER JH: An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am Heart J 125: 620-625, 1993
66. BISSETT D, KERR DJ, CASSIDY J, MEREDITH P, TRAUGOTT U, KAYE SB: Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64:1168-1171, 1991
67. PIRKER R, KEILHAUER G, RASCHACK M, LECHNER C, LUDWIG H: Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int J Cancer 45:916-919, 1990
68. WAINER IW: Stereoisomers in clinical oncology: Why is it important to know what the right and left hands are doing. Ann Oncol 4(Suppl 2):S7-S13, 1993
69. SCHEITHAUER W, SCHENK T, CZEJKA M: Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil. Br J Cancer 68:8-9, 1993
70. MICKISCH GH, MERLINO GT, AIKEN PM, GOTTESMANN MM, PASTAN I: New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. J Urol 146:447-453, 1991